Biotech Stocks: The New Year Heralds a Transition in Stem Cell Development – Kapitall Blog (blog)
| Kapitall Blog (blog) Jason Kolbert, managing director for biotechnology research at Maxim Group, leverages his deep understanding of the stem cell space to uncover viable therapies that double as excellent business models. In this interview with The Life Sciences Report, … |
